financetom
Business
financetom
/
Business
/
SFIO probe against DHFL for alleged financial irregularities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SFIO probe against DHFL for alleged financial irregularities
Nov 1, 2019 12:39 PM

The government has ordered an SFIO (Serious Fraud Investigation Office) probe into alleged financial irregularities at mortgage lender DHFL after finding instances of suspected fund diversions, according to a source.

Dewan Housing Finance Ltd (DHFL) came under the scanner in the wake of allegations that the company had siphoned off Rs 31,000 crore worth bank loans through layers of shell entities.

The Ministry of Corporate Affairs carried out a detailed examination of the allegations of financial misdoings against the company's promoters through the Registrar of Companies (RoC).

The RoC report indicated suspected fund diversions at the company, following which the ministry has asked the Serious Fraud Investigation Office (SFIO) to probe the case, as per the source.

On October 29, a senior official said there were good enough reasons to refer the DHFL matter to the SFIO. The probe agency comes under the ministry.

Separately, a forensic audit by KPMG has reportedly found massive fund diversion by the promoters.

DHFL, the third-largest mortgage lender in the country, had sought a Rs 15,000-crore lifeline from the lenders as they finalise the resolution plan, which may also include picking up 51 percent equity in the company by converting their debt into equity.

First Published:Nov 1, 2019 8:39 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alight's $1.2 Billion Business Sale Likely to Drive Stronger Gross Margins, Higher Recurring Revenue Over Mid-Term, Wedbush Says
Alight's $1.2 Billion Business Sale Likely to Drive Stronger Gross Margins, Higher Recurring Revenue Over Mid-Term, Wedbush Says
Aug 8, 2024
12:27 PM EDT, 08/08/2024 (MT Newswires) -- Alight's (ALIT) closing of the $1.2 billion sale of its payroll and professional services business negatively impacted its Q2 revenue but is expected to drive stronger gross margins and higher recurring revenue, over the mid-term, Wedbush said in a note to clients Thursday. The company's total revenue in Q2 fell 4% year-over-year to...
AxoGen Appoints Michael Dale as Chief Executive
AxoGen Appoints Michael Dale as Chief Executive
Aug 8, 2024
12:21 PM EDT, 08/08/2024 (MT Newswires) -- AxoGen ( AXGN ) said Thursday that it appointed Michael Dale as chief executive, effective Friday. Dale succeeds Karen Zaderej who will remain with AxoGen ( AXGN ) in an advisory role for nine months, according to the company. Dale's past executive leadership roles span both public and private medical device companies, the...
Update: Market Chatter: Apple Planning New Mac Mini Version
Update: Market Chatter: Apple Planning New Mac Mini Version
Aug 8, 2024
12:30 PM EDT, 08/08/2024 (MT Newswires) -- (Updates to include additional details in the third and fourth paragraphs and a request for comment in the fifth paragraph.) Apple ( AAPL ) is planning a new model of the Mac mini that is expected to be released later this year, Bloomberg reported Thursday, citing people with knowledge of the matter. The...
Kura Oncology Says FDA Clears Ziftomenib Clinical Study in Advanced GIST
Kura Oncology Says FDA Clears Ziftomenib Clinical Study in Advanced GIST
Aug 8, 2024
12:28 PM EDT, 08/08/2024 (MT Newswires) -- Kura Oncology ( KURA ) said Thursday that the US Food and Drug Administration has cleared the investigational new drug application for ziftomenib to treat advanced gastrointestinal stromal tumors, or GIST. The company said it plans to start a phase 1 first-in-human trial of ziftomenib plus imatinib in patients with advanced GIST in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved